We recently published a list of 9 Stocks Jim Cramer Talked About. In this article, we are going to take a look at where ...

Complementary discoveries have the potential to enhance treatment options for antibiotic-resistant infections. Researchers at ...

This new tool, known as minimal, versatile genetic perturbation technology (mvGPT), combines the powers of gene editing, ...

RFK Jr.'s comments about the gene-editing technology raise a question about how he would regulate it as head of HHS.

The HAELO trial will assess the therapy’s safety and efficacy in 60 adult subjects with Type I or Type II HAE.

CRISPR & Cas Genes Market Growing funding in gene therapy worldwide is a prominent factor driving the CRISPR & Cas genes market.

The two companies claim AGN-151587 (EDIT-101) for Leber congenital amaurosis type 10 (LCA10) – an inherited form of blindness – is the first ‘in vivo’ CRISPR medicine to be administered to ...

CRISPR Therapeutics is developing CTX112 for ... including the clinical trial for CTX211™ in Type 1 diabetes (T1D) and subsequent next generation programs. These programs focus on allogeneic ...

"As CRISPR therapies enter the clinic ... To find out, Zhang's team used a specialized type of mass spectrometry to identify and analyze the Cas9 and Cas 12 protein fragments recognized by ...

Learn more about whether Catalyst Pharmaceuticals, Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

and the type of science I want to do,” he says. Beyond the lab, he’s also designing an outreach initiative to engage high school students through what he calls “CRISPR in a Box.” ...